Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

PURPOSE: Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells with impaired compensatory DNA damage responses through ATM loss) as monotherapy and combined with DNA-damaging drugs such as carboplatin. PATIENTS AND METHODS: This phase I trial asses...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Yap, Timothy A., O’Carrigan, Brent, Penney, Marina S., Lim, Joline S., Brown, Jessica S., de Miguel Luken, Maria J., Tunariu, Nina, Perez-Lopez, Raquel, Rodrigues, Daniel Nava, Riisnaes, Ruth, Figueiredo, Ines, Carreira, Suzanne, Hare, Brian, McDermott, Katherine, Khalique, Saira, Williamson, Chris T., Natrajan, Rachael, Pettitt, Stephen J., Lord, Christopher J., Banerji, Udai, Pollard, John, Lopez, Juanita, de Bono, Johann S.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2020
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7499606/
https://ncbi.nlm.nih.gov/pubmed/32568634
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02404
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky